ArticleHaematologica2024

Superior outcomes and high-risk features with carfilzomib, lenalidomide, and dexamethasone combination therapy for patients with relapsed and refractory multiple myeloma: results of the multicenter KMMWP2201 study.

Ji Hyun Lee et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.